Rezurock access in Qatar: the MOPH-PD named-patient pathway
How patients in the State of Qatar legally obtain Rezurock (belumosudil) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Qatar access Rezurock (belumosudil) for chronic graft-versus-host disease (cGVHD) in adult and pediatric patients aged 12 years and older after failure of at least two prior lines of systemic therapy through the MOPH-PD named-patient pathway, a the Pharmacy and Drug Control Department of the Qatar Ministry of Public Health-administered mechanism that allows a Qatari-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in QAR.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Qatari patients need Rezurock through the named-patient pathway
The State of Qatar operates a structured pharmaceutical regulatory environment. Rezurock (belumosudil) is regulated through MOPH-PD (the Pharmacy and Drug Control Department of the Qatar Ministry of Public Health) channels, and a Qatari family asking for Rezurock is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.
Four converging patterns drive these cases. First, indication lag. Rezurock's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. Hamad Medical Corporation public coverage, QLM, and GIG Gulf Qatar each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Qatar or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.
In each pattern, the MOPH-PD named-patient pathway is the mechanism that connects a Qatari-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Rezurock is an oral selective rho-associated coiled-coil kinase 2 (ROCK2) inhibitor administered once daily, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.
Current regulatory status of Rezurock in Qatar
Rezurock (belumosudil; Kadmon / Sanofi following the 2021 acquisition) is an oral selective Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, FDA-approved in 2021 for chronic graft-versus-host disease (cGVHD) in adult and paediatric patients aged 12 years and older after failure of at least two prior lines of systemic therapy. The drug is administered once daily at 200 mg.
As of 2026-05-31, no public Qatar MOPH record of a marketing authorisation for belumosudil has been observed. Access proceeds through the MOPH Department of Pharmacy and Drug Control as a named-patient file under Qatar Law No. 3 of 1983.
The cGVHD indication restricts dispensing to centres with allogeneic hematopoietic stem cell transplant (allo-HSCT) follow-up. The file specifies the cGVHD NIH consensus criteria documentation, the involved-organ scoring per the NIH cGVHD score, the prior lines of systemic therapy (corticosteroids, calcineurin inhibitors, mTOR inhibitors, ibrutinib, ruxolitinib, ECP, rituximab as appropriate), and the dosing plan.
For adolescent patients aged 12 to 17, Sidra Medicine's paediatric BMT service is the principal Qatari dispensing centre and cross-referrals to Sidra for paediatric cGVHD are routine. For adult cGVHD patients (the larger cohort), the HMC adult haematology-BMT service at NCCCR is the dispensing route.
Last verified by ARCH-74: 2026-05-31.
Named tertiary centres in Qatar where Rezurock is dispensed
Belumosudil for cGVHD is dispensed at centres with allo-HSCT follow-up. In Qatar:
- Hamad Medical Corporation - National Center for Cancer Care and Research (NCCCR), Doha - Adult Haematology and BMT Programme; the principal adult dispensing centre for post-allo-HSCT cGVHD.
- Sidra Medicine, Doha - Paediatric Haematology, Oncology, and BMT service; principal paediatric dispensing centre for cGVHD patients aged 12 to 17 (the FDA-labelled lower age limit). Source: Sidra Medicine.
- Hamad General Hospital, Doha - Department of Internal Medicine, follow-up referral to NCCCR for haematology-BMT care.
- Al-Ahli Hospital, Doha - private tertiary, post-transplant follow-up for insured / expatriate cases.
The Qatari adult BMT volume is small relative to regional centres (KFSHRC in Saudi, Cleveland Clinic Abu Dhabi); some Qatari cGVHD patients receive their initial allo-HSCT abroad and return to NCCCR for cGVHD management with belumosudil.
Local pricing reference for Rezurock in Qatar
US WAC reference for Rezurock (belumosudil, 200 mg oral tablets) is in the order of USD 18,000 to USD 22,000 per 30-day supply at the FDA-labelled 200 mg once-daily regimen. Source: Rezurock FDA Prescribing Information.
No public QAR reference price for belumosudil has been observed on MOPH or NCCCR published lists as of 2026-05-31. QAR is pegged to USD at approximately 3.64 QAR per USD; the per-month indicative QAR reference is approximately QAR 66,000 to QAR 80,000.
Price snapshot date: 2026-05-31. Concomitant cGVHD therapies (corticosteroids on taper, calcineurin inhibitor levels, ECP if available) are locally sourced and not part of the import file.
Country-specific access barriers for Rezurock in Qatar
The principal access barrier for belumosudil in Qatar is the prior-line-of-therapy documentation. The FDA label requires failure of at least two prior lines of systemic cGVHD therapy. The file references each prior line (drug name, dosing, duration, response classification per the NIH cGVHD response criteria, reason for discontinuation). NCCCR and Sidra BMT services typically have the complete prior-therapy documentation in the electronic medical record.
Public-sector funding posture: HMC NCCCR's funding pathway for post-transplant cGVHD care covers Qatari nationals; the high-cost-medicine budget supports belumosudil for confirmed cGVHD eligibility. For Sidra-managed paediatric cases the HMC funding integration applies. For expatriate post-transplant cGVHD patients, private insurance (QLM, AXA Gulf Qatar, Daman, Allianz Care, Bupa Global) coverage requires demonstrated post-transplant indication and case-by-case pre-authorisation.
Drug-drug interaction management is meaningful: belumosudil is a CYP3A4 substrate and concomitant strong CYP3A4 inhibitors / inducers require dose adjustment. Post-transplant patients frequently receive azole antifungal prophylaxis (voriconazole, posaconazole) which are strong CYP3A4 inhibitors; the dispensing pharmacy at NCCCR and Sidra reviews concomitant prophylaxis and adjusts belumosudil dose accordingly per the FDA label.
The ambient-storage oral tablets simplify customs handling. Each MOPH permit covers a defined supply window; chronic cGVHD therapy patients re-apply per cycle (typical: every 3 months).
Recent local regulatory news touching Rezurock or its drug class in Qatar
No MOPH bulletin specifically naming belumosudil or the ROCK2-inhibitor class has been observed in the last twelve months on the MOPH media centre as of 2026-05-31. Adjacent context:
- FDA labelling updates on belumosudil since the 2021 initial approval have continued to refine paediatric dosing recommendations. Source: FDA Drugs@FDA database.
- NCCCR's BMT service continues to publish operational updates; the cGVHD MDT and the paediatric cGVHD pathway with Sidra are established cross-referral patterns. Source: NCCCR / HMC.
What your physician needs to provide
For a Qatari-licensed specialist prescribing Rezurock through the MOPH-PD pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for chronic graft-versus-host disease (cGVHD) in adult and pediatric patients aged 12 years and older after failure of at least two prior lines of systemic therapy, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Rezurock is the appropriate next step given an oral selective rho-associated coiled-coil kinase 2 (ROCK2) inhibitor administered once daily.
The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Rezurock (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.
The treating physician's Qatari license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.
Common questions about Rezurock in Qatar
Will Hamad Medical Corporation public coverage, QLM, and GIG Gulf Qatar cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Rezurock is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is the FDA-approved indication recognised by MOPH-PD? The MOPH-PD named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; MOPH-PD review focuses on the clinical justification rather than re-litigating the FDA decision.
My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Qatari-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. Qatar Council for Healthcare Practitioners (QCHP) and the MOPH verifies the active license; the MOPH-PD application records both the prescribing physician and the dispensing facility.
Can I receive Rezurock at home? The dispensing facility must be Qatari-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.
What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.
Where Reserve Meds fits in Rezurock cases
Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace MOPH-PD, and we do not replace your dispensing pharmacy. For Rezurock specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Qatar, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Rezurock case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the MOPH-PD application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Qatar specialty referral concentrates at Hamad General, NCCCR at HMC, and Sidra Medicine; named-patient files flow through the Pharmacy and Drug Control Department of the Qatar Ministry of Public Health where applicable. Rezurock is an oral ROCK2 inhibitor for chronic GVHD after two prior lines of systemic therapy; named-patient files document the cGVHD organ involvement (NIH consensus criteria), prior lines including a corticosteroid and a second-line agent, and the baseline liver function (transaminase elevation is on the warnings). The UAE cell-therapy and transplant centres manage these cases.
Next step
If your Qatari physician has prescribed Rezurock and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.